The aim of our study was to evaluate the diagnostic performance of plasma PCSK9 in systemic inflammatory response syndrome (SIRS)/sepsis patients with COVID-19 disease, and to compare these plasma PCSK9 levels with established laboratory markers of inflammation and sepsis in the context of underlying comorbidities. Here, PCSK9 is linked to Sepsis.